ArticlePharmaceutical research2011
Finding promiscuous old drugs for new uses.
Article in Pharmaceutical research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- The Pharmacorank Search Tool for the Retrieval of Prioritized Protein Drug Targets and Drug Repositioning Candidates According to Selected Diseases.Biomolecules · 2022Article
- Machine Learning Models forMolecular pharmaceutics · 2022Article
- In vitro effectivity of three approved drugs and their synergistic interaction against Leishmania infantum.Biomedica : revista del Instituto Nacional de Salud · 2020Article
- Dapagliflozin Promotes Neovascularization by Improving Paracrine Function of Skeletal Muscle Cells in Diabetic Hindlimb Ischemia Mice Through PHD2/HIF-1α Axis.Frontiers in pharmacology · 2020Article
- Artificial intelligence and big data facilitated targeted drug discovery.Stroke and vascular neurology · 2019Review
- Exploration of interaction scoring criteria in the CANDO platform.BMC research notes · 2019Article
- Isolation and identification of two alkaloid structures with radical scavenging activity from Actinokineospora sp. UTMC 968, a new promising source of alkaloid compounds.Molecular biology reports · 2018Article
- Article
- Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.Mini reviews in medicinal chemistry · 2016Review
- Article
- Identification of Nitazoxanide as a Group I Metabotropic Glutamate Receptor Negative Modulator for the Treatment of Neuropathic Pain: An In Silico Drug Repositioning Study.Pharmaceutical research · 2015Article
- Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets.Journal of chemical information and modeling · 2015Article
- Screening of novel inhibitors targeting lactate dehydrogenase A via four molecular docking strategies and dynamics simulations.Journal of molecular modeling · 2015Article
- Machine learning models identify molecules active against the Ebola virusF1000Research · 2015Article
- World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.World journal of methodology · 2014Review
- Collaboration for rare disease drug discovery research.F1000Research · 2014Article
- Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development.Frontiers in oncology · 2013Review
- Identification of novel activators of constitutive androstane receptor from FDA-approved drugs by integrated computational and biological approaches.Pharmaceutical research · 2013Article
- Article
- Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
From research published in the last six years we have identified 34 studies that have screened libraries of FDA-approved drugs against various whole cell or target assays. These studies have each identified one or more compounds with a suggested new bioactivity that had not been described previously. We now show that 13 of these drugs were active against more than one additional disease, thereby suggesting a degree of promiscuity. We also show that following compilation of all the studies, 109 molecules were identified by screening in vitro. These molecules appear to be statistically more hydrophobic with a higher molecular weight and AlogP than orphan-designated products with at least one marketing approval for a common disease indication or one marketing approval for a rare disease from the FDA's rare disease research database. Capturing these in vitro data on old drugs for new uses will be important for potential reuse and analysis by others to repurpose or reposition these or other existing drugs. We have created databases which can be searched by the public and envisage that these can be updated as more studies are published.
Indexed as
Identifiers
21607776What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.